7 December 2023 - EnGeneIC has achieved a significant milestone with the granting of FDA fast track designation for its ...
7 December 2023 - Next generation gene transfer therapy to treat Duchenne receives FDA fast track Designation. ...
5 December 2023 - Recent Phase 3 monotherapy first results demonstrated complete response rate of 75.7% at any time. ...
30 November 2023 - Previously reported results from ongoing proof of concept study showed extensive metabolic correction, continued cognitive, motor, and ...
29 November 2023 - This is the third fast track designation for BI 764532. ...
28 November 2023 - Designation is for second or third-line treatment of patients with disease progression following treatment with endocrine therapy ...
28 November 2023 - FDA fast track designation for bile duct cancer granted for CF33-hNIS (Vaxinia) MAST clinical program. ...
27 November 2023 - Pivotal Phase 3 study of olvi-vec in platinum resistant/refractory ovarian cancer initiated in September 2022. ...
22 November 2023 - Phase 1/2 Harmony data for ADP101 recently presented at the 2023 American College of Asthma, Allergy and ...
15 November 2023 - CM-101's unique dual anti-fibrotic and anti-inflammatory activity has disease modifying potential in this poorly treated condition. ...
14 November 2023 - SonALAsense today announced that the US FDA has granted fast track designation to the development program of ...
10 November 2023 - Rznomics announced today that it has received fast track designation from the US FDA for RZ-001, for ...
6 November 2023 - AVB-101 is an investigational gene therapy delivered as a one time infusion directly to the brain, enabling ...
31 October 2023 - If approved, CSX-1004 would be the first FDA approved therapy for prevention of fentanyl-related overdose. ...
30 October 2023 - LS009 demonstrated promising efficacy in Phase 1 Study with 36.4% clinical response in relapsed/refractory peripheral T-cell lymphomas; ...